Stay updated with breaking news from Mayo stage. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Findings from an analysis of treatment patterns for patients with systemic amyloid light chain amyloidosis have demonstrated that several unmet needs exist, including timely diagnosis and limited survival outcomes for patients with advanced disease. ....
Prothena Corporation plc: Prothena Announces Phase 3 VITAL Clinical Trial Results Published in Blood Showing Survival Benefit in Patients with Mayo Stage IV AL Amyloidosis Treated with Birtamimab finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
First time published in a peer-reviewed journal: birtamimab is the only investigational drug that has shown a significant survival benefit in patients with Mayo Stage IV AL amyloidosis in a double-blind placebo-controlled clinical trial
A significant improvement in time to all-cause mortality at month 9 was observed with birtamimab versus placebo and remained consistent across all key baseline variables in a post hoc analysis of patients with Mayo Stage IV AL amyloidosis
Birtamimab is currently being studied in the confirmatory Phase 3 clinical trial, AFFIRM-AL, in patients with Mayo Stage IV AL amyloidosis; topline data is expected in 2024 ....
Prothena Announces Phase 3 VITAL Clinical Trial Results Published in Blood Showing Survival Benefit in Patients with Mayo Stage IV AL Amyloidosis Treated with Birtamimab streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Stock Market | FinancialContent Business Page financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.